School of Natural Sciences, Massey University, Palmerston North, New Zealand.
Malignant Hyperthermia Diagnostic Unit, Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Parkville, VIC, Australia.
Br J Anaesth. 2022 Dec;129(6):879-888. doi: 10.1016/j.bja.2022.08.029. Epub 2022 Oct 6.
A major bottleneck to the introduction of noninvasive presymptomatic diagnostic tests for the pharmacogenetic disorder malignant hyperthermia is the lack of functional data for associated variants.
We screened 50 genes having a potential role in skeletal muscle calcium homeostasis using the HaloPlex™ (Agilent Technologies, Santa Clara, CA, USA) target enrichment system and next-generation sequencing. Twenty-one patients with a history of a clinical malignant hyperthermia reaction together with a positive in vitro contracture test were included. Eight variants in RYR1 were subsequently introduced into the cDNA for the human ryanodine receptor gene and tested in cultured human embryonic kidney (HEK293) cells for their effect on calcium release from intracellular stores in response to the ryanodine receptor-1 agonist 4-chloro-m-cresol using fura-2 as calcium indicator. Each variant was subjected to in silico curation using the European Malignant Hyperthermia Group scoring matrix and ClinGen RYR1 variant curation expert panel guidelines.
Potentially causative RYR1 variants were identified in 15 patients. Of these, two families carried two RYR1 variants, five variants had been previously reported as 'pathogenic', two variants had been previously reported as 'likely benign', and eight were of 'uncertain significance'. Of these eight variants, four showed hypersensitivity to 4-chloro-m-cresol. Three variants were reclassified as either 'pathogenic' or 'likely pathogenic'. Two were classified as 'benign', whilst three remained of 'uncertain significance'.
Three (p.Tyr1711Cys, p.Val2280Ile, and p.Arg4737Gln) additional variants can be added to the list of RYR1 disease-associated variants managed by the European Malignant Hyperthermia Group. These can therefore be used diagnostically in the future. Three variants (p.Glu2348Gly, p.Asn2634Lys, and p.Arg3629Trp) that remained classified as of uncertain significance require further family studies or a different functional test to determine clinical relevance in malignant hyperthermia.
将非侵入性的、用于预测恶性高热的遗传疾病的诊断检测手段引入临床应用的主要瓶颈是缺乏与相关变异相关的功能数据。
我们使用 HaloPlex™(Agilent Technologies,Santa Clara,CA,USA)靶向富集系统和下一代测序对 50 个可能参与骨骼肌钙稳态的基因进行了筛选。研究共纳入了 21 名有恶性高热临床反应史和体外收缩试验阳性的患者。随后,我们将 RYR1 中的 8 个变异引入人类兰尼碱受体基因的 cDNA 中,并在培养的人胚肾(HEK293)细胞中用荧光素作为钙指示剂,检测它们对 4-氯间甲酚引发的钙从细胞内库释放的影响,4-氯间甲酚是兰尼碱受体 1 激动剂。每个变异均使用欧洲恶性高热组评分矩阵和 ClinGen RYR1 变异管理专家小组指南进行了计算机分析。
在 15 名患者中发现了可能导致疾病的 RYR1 变异。其中两个家系携带两种 RYR1 变异,五种变异先前被报道为“致病性”,两种变异先前被报道为“可能良性”,八种变异为“意义不明”。这八种变异中,有四种对 4-氯间甲酚表现出超敏性。三种变异被重新分类为“致病性”或“可能致病性”。两种被分类为“良性”,三种仍为“意义不明”。
可以在欧洲恶性高热组管理的 RYR1 疾病相关变异列表中添加三种(p.Tyr1711Cys、p.Val2280Ile 和 p.Arg4737Gln)新的变异,因此可以在未来用于诊断。三种变异(p.Glu2348Gly、p.Asn2634Lys 和 p.Arg3629Trp)仍然被归类为意义不明,需要进一步的家系研究或不同的功能测试来确定其在恶性高热中的临床意义。